Categories
Medical Articles

Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy

Na Qua, Yiming Meng, Mike K. Handley, Chunyan Wang, Fengping Shan

10.1016/j.intimp.2021.107714

Highlights

LDNs may exert effect as crosspoint between toll-like receptor signal and tumor apoptotic pathway.•

LDNs could enhance antitumor response of immune cells via crossing molecular pathways.•

LDNs might improve unbalanced status of internal homeostasis universally in cancer patients.

Leave a Reply

Your email address will not be published.